68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients

Editorial

Valentina Ambrosini et al. Nucl Med Commun. 2008 May.

. 2008 May;29(5):415-7.

doi: 10.1097/MNM.0b013e3282ffd70d.

No abstract available

Comment on

68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ. Gabriel M, et al. J Nucl Med. 2007 Apr;48(4):508-18. doi: 10.2967/jnumed.106.035667. J Nucl Med. 2007. PMID: 17401086 Clinical Trial.
Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, Herrmann T, Haberkorn U. Buchmann I, et al. Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1617-26. doi: 10.1007/s00259-007-0450-1. Epub 2007 May 23. Eur J Nucl Med Mol Imaging. 2007. PMID: 17520251